Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, discusses microstructure intelligence in more detail in part 2 of this preview of the company’s keynote presentation at AAPS PharmSci 360.
News|Articles|March 22, 2019
- Pharmaceutical Technology\'s In the Lab eNewsletter-04-03-2019
- Volume 14
- Issue 4
New Protein Characterization Technique Unveiled at Pittcon 2019
Author(s)Pharmaceutical Technology Editors
Microsaic Systems showcased its new MiD ProteinID point-of-need mass spectrometer at Pittcon in Philadelphia, PA, from March 18–21, 2019.
Advertisement
Microsaic’s MiD ProteinID point-of-need mass spectrometer allows users to verify target proteins, metabolites, by-products and feed-stocks throughout the whole bioprocessing value chain and offers laboratory-level performance on an industrial scale.
By providing deterministic characterization for proteins and small molecules at the point-of-need, the mass spectrometer helps to ensure critical process parameters and critical quality attributes are attained timely, and simultaneously, which is vital for biologics compliance, according to the company.
“Our MiD ProteinID system is a process analytical game changer. Bioprocessing operators can now monitor feedstocks, metabolites, and target proteins in just one measurement, accelerating time-to-market for new biologics and assisting in process and product compliance,” said Glenn Tracey, CEO, Microsaic Systems, in a company press release. “Mass spectrometry can now offer superlative performance to high-value manufacturing industries at the point-of-need, providing much greater insights over ubiquitous optical sensors, such as [ultraviolet], Raman, and [near infrared].”
The mass spectrometer was showcased at booth 4131 at Pittcon 2019 in Philadelphia, PA, which took place from March 17–21, 2019.
Source:
Articles in this issue
over 7 years ago
Ensuring Robust Stability Testing for Product Longevityover 7 years ago
Lonza Strengthens Cell Capabilitiesover 7 years ago
Clinical Water Purification System Gets Digital Updateover 7 years ago
Lilly and ImmuNext Announce Licensing and Research Collaborationover 7 years ago
Dual Impeller Single-Use Bioreactorover 7 years ago
Tosoh Bioscience Introduces New MALS Detector at Pittcon 2019Advertisement
Related to this article
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
Advertisement
Advertisement